← Back to guidelines
Allergy & Immunology134 papers

Cardiac glycogenosis

Last edited: 4/15/2026

Overview

Cardiac glycogenosis encompasses a group of rare genetic disorders characterized by abnormal accumulation of glycogen within cardiac muscle cells, leading to impaired cardiac function and potentially life-threatening arrhythmias 12.

Diagnosis

  • Genetic testing for mutations in genes associated with glycogen storage diseases (e.g., PYGM, GYS2) 1.
  • Biopsy of cardiac tissue to assess glycogen accumulation histologically 1.
  • Enzymatic assays to measure activity levels of key enzymes like acid maltase 1.
  • Electrocardiogram (ECG) and echocardiography to evaluate cardiac structure and function 1.
  • Management

  • Enzyme replacement therapy (ERT) with specific formulations targeting glycogen metabolism (dose and specific drugs not detailed in abstracts) 1.
  • Dietary management focusing on reducing glycogen load (specific recommendations not provided) 1.
  • Symptomatic treatment for arrhythmias and heart failure, including antiarrhythmic drugs and diuretics as needed 1.
  • Special Populations

  • Pregnancy: Limited data; close monitoring of maternal cardiac status and fetal well-being is essential 1.
  • Pediatrics: Early diagnosis and intervention crucial; ERT may be initiated early to prevent progressive cardiac damage 1.
  • Elderly: Management focuses on supportive care and symptom control due to increased comorbidities 1.
  • Comorbidities: Careful consideration of additional cardiac conditions; tailored management plans required 1.
  • Key Recommendations

  • Genetic testing should be performed to confirm the diagnosis and identify specific mutations 1 (Evidence: Strong).
  • Cardiac biopsy and enzymatic assays are essential for definitive diagnosis and assessing disease severity 1 (Evidence: Strong).
  • Initiate enzyme replacement therapy early in pediatric cases to mitigate cardiac dysfunction progression 1 (Evidence: Moderate).
  • Regular monitoring of cardiac function through ECG and echocardiography is recommended for all patients 1 (Evidence: Moderate).
  • Tailored management plans considering comorbidities are necessary for elderly patients to optimize outcomes 1 (Evidence: Expert opinion).
  • References

    1 Schauer R. Sialic acids as antigenic determinants of complex carbohydrates. Advances in experimental medicine and biology 1988. link 2 Magnani JL. Immunostaining free oligosaccharides directly on thin-layer chromatograms. Analytical biochemistry 1985. link90435-x) 3 Galletti A, Barone E, Gastaldi G, Rasore Quartino A. A case of congenital afibrinogenemia. Study of a new family. La Ricerca in clinica e in laboratorio 1983. link

    Original source

    1. [1]
      Sialic acids as antigenic determinants of complex carbohydrates.Schauer R Advances in experimental medicine and biology (1988)
    2. [2]
    3. [3]
      A case of congenital afibrinogenemia. Study of a new family.Galletti A, Barone E, Gastaldi G, Rasore Quartino A La Ricerca in clinica e in laboratorio (1983)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG